Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs

Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on RNA-mod­u­lat­ing ther­a­peu­tics for rare dis­eases with high unmet need, announced the appoint­ment of Larry Bell, M.D. as its Vice President of Regulatory Affairs. Dr. Bell will be based in the USA.
Dr. Bell has more than 18 years expe­ri­ence in run­ning reg­u­la­to­ry affairs for world-lead­ing phar­ma­ceu­ti­cal com­pa­nies includ­ing Merck, Bristol-Myers Squibb, Aventis and Amgen. Before set­ting up his own con­sul­tan­cy, in his most recent role he was Vice President and Global Head of Regulatory Affairs at GE Healthcare. He com­plet­ed his MD at the University of Texas Medical Branch.
At Prosensa, Dr. Bell will be over­see­ing the company’s glob­al reg­u­la­to­ry activ­i­ties. Importantly, giv­en the ground-break­ing nature of Prosensa’s exon-skip­ping ther­a­pies and the need to ensure an effi­cient route to patients, he will also be instru­men­tal in devel­op­ing appro­pri­ate reg­u­la­to­ry strate­gies and effec­tive rela­tion­ships with the rel­e­vant author­i­ties in USA, Europe and Japan.
Commenting on his appoint­ment, Dr. Bell said: “This is a key time to be join­ing the Prosensa team. As the orphan drugs space grows in size and scope, there are many reg­u­la­to­ry con­sid­er­a­tions that need to be addressed in order for new drugs to reach the patients that need them. I look for­ward to help­ing progress Prosensa’s cut­ting-edge ther­a­pies through the reg­u­la­to­ry process.”
Prosensa’s Chief Medical Officer, Giles Campion, com­ment­ed: “Prosensa has cre­at­ed an exten­sive clin­i­cal devel­op­ment pro­gram that aims to tar­get dif­fer­ent sub­pop­u­la­tions of Duchenne mus­cu­lar dys­tro­phy patients. Pioneering the reg­u­la­to­ry path­way for this new class of drugs is an impor­tant fac­tor in our focus to bring treat­ments to patients as fast as pos­si­ble. Larry’s exten­sive sci­en­tif­ic expe­ri­ence, both in research and reg­u­la­to­ry affairs, com­bined with his med­ical expe­ri­ence, brings valu­able new skills into the com­pa­ny.”

Leave a Reply

Your email address will not be published. Required fields are marked *